MyFinsight
Home
Blog
About
Proceeds from issuance of
common shares from atm,...
$20,180
(-99.54%↓ Y/Y)
Net cash provided by
financing activities
$20,180
(-99.57%↓ Y/Y)
Net increase
(decrease) in cash
-$498,260
(-115.03%↓ Y/Y)
Canceled cashflow
$20,180
Accounts payable and
accrued expenses
$202,524
(163.46%↑ Y/Y)
Prepaid insurance
-$44,263
Stock-based compensation
$8,253
(-93.32%↓ Y/Y)
Interest receivable
-$823
Change in fair value of
warrant liability
$108
(104.79%↑ Y/Y)
Net cash used in
operating activities
-$518,440
(62.57%↑ Y/Y)
Canceled cashflow
$255,971
Interest income
$34,512
(29.28%↑ Y/Y)
Net loss
-$773,702
(55.98%↑ Y/Y)
Canceled cashflow
$34,512
Prepaid financing costs
$709
Research and development
$308,747
(-49.81%↓ Y/Y)
Operating expenses
$302,800
(-53.59%↓ Y/Y)
Salaries
$125,000
(-50.00%↓ Y/Y)
Insurance
$63,414
(-55.71%↓ Y/Y)
Stock-based compensation
$8,253
(-93.32%↓ Y/Y)
Back
Back
Cash Flow
Bone Biologics Corp (BBLG)
Bone Biologics Corp (BBLG)
source: myfinsight.com